News from spherix global insights A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 10, 2019, 14:10 ET Positive Growth of Eli Lilly's Taltz and Stabilization of Novartis' Cosentyx in Psoriasis May be an Indicator for Future Psoriatic Arthritis Market Shift

Novartis' Cosentyx was first approved by the FDA for the treatment of psoriasis in January 2015, followed by a label extension for both psoriatic...


Oct 07, 2019, 04:47 ET Benefitting From Expanded Access in Europe, Roche's Ocrevus is on Track to Displace Biogen's Tysabri in Neurologist Preference and Share Among Patients with Relapsing Forms of Multiple Sclerosis Over the Next Six Months

Expanded access to Merck KGaA's Mavenclad and Roche's Ocrevus in Europe has significantly shifted neurologists' reported disease-modifying therapy...


Sep 26, 2019, 08:36 ET Strong Uptake in the Expanding Preventive-Treated Episodic Migraine Segment Has Propelled Eli Lilly's Third-to-Market Emgality to Second Place in the Anti-CGRP Class ― Surpassing Teva's Ajovy

Nine months post launch, specialists' self-reported share for Eli Lilly's Emgality has surpassed (for the first time) that of Teva's Ajovy among...


Sep 17, 2019, 13:05 ET US Nephrologists Beginning to Trial AstraZeneca's LOKELMA (zirconium sodium cyclosilicate) but Unclear on Differentiation from Vifor/Relypsa's VELTASSA (patiromer FOS)

After two Complete Response Letters resulting in lengthy approval delays, AstraZeneca was finally able to introduce Lokelma, its novel treatment for...


Sep 13, 2019, 06:55 ET Novartis' Cosentyx and Pfizer's Xeljanz Leave the Most on the Table with Psoriatic Arthritis Switch Brands, According to Spherix Global Insights

The fourth annual patient chart audit included in Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in PsA (US) service includes the...


Sep 11, 2019, 07:30 ET Unimpeded by Allergan's Botox Dominance, Amgen/Novartis' Aimovig, Teva's Ajovy, and Eli Lilly's Emgality Use at the Patient Level is More Robust Within the Episodic Migraine Segment Than Physicians Are Aware of

Contributing physicians appear to underestimate their use of the anti-calcitonin gene-related peptide (CGRP) therapies in patients with episodic...


Sep 06, 2019, 06:50 ET Recent Studies Reveal Flare Rates Among Dupixent-Treated Patients with Moderate-to-Severe Atopic Dermatitis

Atopic dermatitis (AD), commonly referred to as eczema, affects millions of children and adults across the globe. In 2017, Regeneron/Sanofi's...


Aug 30, 2019, 04:10 ET Biosimilars and JAK Inhibitors Continue to Gain Popularity in the EU Rheumatoid Arthritis Market, According to Spherix Global Insights

Twice a year, Spherix collects the responses of ~250 EU5 rheumatologists as part of their RealTime Dynamix™: Rheumatoid Arthritis (EU) service. This...


Aug 27, 2019, 11:03 ET Spherix Global Insights Named One of Philadelphia's Fastest Growing Companies

Spherix Global Insights, a market intelligence firm providing biopharma clients an independent perspective within immunology, nephrology, and...


Aug 13, 2019, 04:53 ET Novartis' Gilenya, Sanofi's Aubagio, Biogen's Tysabri and Tecfidera Capture the Majority of Recent Switches in the European Multiple Sclerosis Market Boosted by Frequent Neurologist Endorsement

According to Spherix's new audit included in the RealWorld Dynamix: DMT Switching in Multiple Sclerosis (EU) service, the relapsing-remitting...


Aug 01, 2019, 12:38 ET US Nephrologists Are Optimistic About the Potential for Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs) for the Treatment of Renal Anemia

In the latest report included in the RealTime Dynamix: Renal Anemia service, which represents the 16th consecutive wave, Spherix Global Insights...


Jul 25, 2019, 10:15 ET Robust Use of Janssen's Tremfya and Positive Early Launch Metrics for AbbVie's Skyrizi May Threaten Growth of IL-17 Inhibitors in US Psoriasis Market, According to Spherix Global Insights

Spherix began tracking the US psoriasis market through its RealTime Dynamix™: Psoriasis (US) service in early 2016, just one year following the...


Jul 19, 2019, 07:19 ET Launch of AbbVie's Upadacitinib Expected to Cause a Stir in the US Rheumatoid Arthritis Market, According to Spherix Global Insights

The latest report included in Spherix's RealTime Dynamix™ Rheumatoid Arthritis (US) independent service comprises the responses of 101 US...


Jul 16, 2019, 14:42 ET Uptake of Biosimilars in the EU5 Blunts Share of AbbVie's Humira and Merck's Remicade in the Crohn's Disease and Ulcerative Colitis Markets, While a Black Cloud of Safety Concerns Still Follows Pfizer's Xeljanz

According to the latest report published as part of Spherix's RealTime Dynamix™: Inflammatory Bowel Disease (EU) service, EU5 gastroenterologists...


Jul 02, 2019, 08:00 ET Eli Lilly's Emgality is Perceived as Increasingly Competitive with Amgen/Novartis' Aimovig and Teva's Ajovy in the US Migraine Prevention Market, as the Anti-CGRP Brand Pulls Ahead on Payer Approval Ease and Overall Prescriber Satisfaction

US neurologists and migraine specialists typically report few clinically relevant points of differentiation between the three brands in the new class ...


Jun 26, 2019, 08:00 ET With Novartis' Mayzent Firmly Positioned for Transitioning Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis Use, EMD Serono's Mavenclad Could Be Most Competitive as an Ideal First Switch Following Efficacy Failure

During the last week of March 2019, both Novartis' Mayzent and EMD Serono's Mavenclad were approved by the FDA as disease-modifying therapies (DMTs)...


Jun 25, 2019, 07:00 ET US Nephrologists Report Few Gains in the CKD-MBD Market for Akebia's Auryxia, Amgen's Parsabiv, and Opko's Rayaldee Despite Reports That They Would Like to Expand Use of All Three Products

According to a survey of 202 nephrologists in late May, use of Parsabiv (etelcalcetide) flatlined between Q1 and Q2, the first quarter to not see...


Jun 05, 2019, 17:16 ET US Gastroenterologists Report VARSITY Trial Data and JAK Inhibitor Safety Concerns Will Impact Their Prescribing Behavior in Ulcerative Colitis, with Potential Implications for Crohn's Treatment

While both the ulcerative colitis (UC) and Crohn's disease markets have remained relatively stable since the prior quarter in terms of brand share...


May 28, 2019, 08:00 ET EMD Serono's Mavenclad Edges Past Novartis' Gilenya in the Recent Switch Segment of Canada's Multiple Sclerosis Market, Although Brand Familiarity Remains An Addressable Barrier

Therapeutic choice for multiple sclerosis (MS) in Canada has expanded substantially over the past two years with Health Canada's November 2017...


May 14, 2019, 11:36 ET US Dermatologists Report a Sizeable Portion of Their Atopic Dermatitis Patients Currently Treated with Sanofi/Regeneron's Dupixent Would be Switched to Another Targeted Therapy if Available

In Spherix's second quarter update of RealTime Dynamix™: Atopic Dermatitis (US), Sanofi/Regeneron's Dupixent continues to grow two years post-launch, ...


Apr 29, 2019, 09:00 ET Biogen's Tecfidera Share of the Multiple Sclerosis Switch Segment Continues a Three-Year Downward Trend to the Benefit of Novartis' Gilenya and Genentech's Ocrevus

According to Spherix's new RealWorld Dynamix™: DMT Switching in Multiple Sclerosis (US) audit, more than half of multiple sclerosis (MS) patients...


Apr 10, 2019, 03:30 ET Preferential First-Line Use of Biogen's Tecfidera and Continued Uptake of Merck KGaA's Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year

Self-reported oral disease-modifying therapy (DMT) class share has increased significantly over the past year in the EU multiple sclerosis (MS)...


Mar 26, 2019, 13:59 ET US Gastroenterologists Project Near-Term Growth of Takeda's Entyvio and Janssen's Stelara for the Treatment of Crohn's Disease, while Anticipated Increased Adoption of Pfizer's Xeljanz in Ulcerative Colitis is Likely to Interrupt Entyvio's Trajectory

At approximately eight months post-launch, Pfizer's Xeljanz is continuing to have success penetrating the US ulcerative colitis (UC) market,...